| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | 公司成立于2000年12月，注册在江苏无锡，营运总部位于上海，是全球公认的具备新药研发实力的领先开放式、全方位、一体化的医药研发服务能力与技术平台。 公司作为开放式的研发服务平台，面向全球小分子化学药企业提供研发服务，拥有包括国内上海、苏州、天津、武汉、常州及美国费城、圣保罗、亚特兰大、圣地亚哥、德国慕尼黑等在内的全球26个研发基地/分支机构，具备向不同规模、不同类型、不同发展阶段的小分子化学药企业提供新药研发产业链各个环节的不同服务的能力，并面向全球持续吸收新技术、新人才，紧跟行业发展趋势，提升自身服务能力。截至目前，公司已经为全球超过3,000家客户提供研发服务，主要客户覆盖全球排名前20位的大型药企及各类新药研发机构。 公司作为拥有全方位服务能力的技术平台，具备提供小分子药物发现、开发、生产及配套的检测、临床试验服务、医疗器械检测及精准医疗研发生产服务的能力。客户可以在小分子新药研发的任何阶段选择选用公司的服务，有效缩短研发周期、提高研发产能。 公司作为拥有一体化服务能力的技术平台，拥有全面的业务覆盖领域，既可以为客户提供阶段性的服务，也可以为客户提供从化合物发现到最终药物上市的全方位服务，截至2017年12月31日，公司为客户在研1,000余项新药开发项目，并同时支持或承载着包括辉瑞、礼来、默沙东等全球多家知名药企200多个临床I-II期、30多个临床III期及商业化阶段的小分子化学药生产。通过一体化技术平台，可以让更多创业者的研发思路有效落地，让更多潜在的突破性创新药进入研发管线，降低新药研发的成本和门槛。 公司开创了业界独特的一体化服务模式和开放式平台模式，并见证了全球小分子医药研发领域的变革。过去的十余年间，从创始之初仅650平方米的化学服务实验室起步，公司恪守最高国际质量监管标准，已经建立了从药物发现到临床前开发，临床试验及小分子化学药生产的贯穿整个新药研发过程的综合服务能力和技术，迅速成长为全球医药研发领域中覆盖全产业链的综合新药研发服务平台。 公司协助客户研发的诸多新药均已通过FDA认证并获批上市，其中诸多新药获得FDA突破性疗法、孤儿药资格认定及FDA―快车通道‖等认定。 公司亦自2015年初开始协助国内客户研发新药并向CFDA提交临床试验新药申报业务，迄今已申报20余例。未来将通过上市许可人制度（MAH）等法规协助国内药企及科研院所着力发展新药研发服务，重点拓展境内客户及定制化服务，帮助中国病人与全球患者同步能使用到最新药物。 在公司研发平台的助力下，越来越多的中国企业正在向世界展现中国的创新智慧。―成为全球医药健康产业最高、最宽和最深的能力和技术平台，让天下没有难做的药，难治的病是公司的宏伟愿景及战略蓝图。 | ||||||||||||||||||||||||
| Main Business | 化学业务、测试业务、生物学业务、细胞及基因疗法 CTDMO 业务、国内新药研发服务业务五大板块 | ||||||||||||||||||||||||
| Legal Representative | 李革 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 张远舟 | ||||||||||||||||||||||||
| Solicitors | 上海市方达律师事务所 | ||||||||||||||||||||||||
| Auditors | 德勤华永会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-2066-3091 | ||||||||||||||||||||||||
| Fax No | 021-5046-3093 | ||||||||||||||||||||||||
| Website | www.wuxiapptec.com.cn | ||||||||||||||||||||||||
| ir@wuxiapptec.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 08/05/2018 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 3.270 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.983 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 18.570 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 114.202B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |